{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "TBRG",
  "name": "TruBridge, Inc.",
  "url": "https://orbyd.app/dossiers/TBRG/",
  "json_url": "https://orbyd.app/dossiers/TBRG.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Terminated, not traded: the IKS Health merger closed 2026-07-09 at $26.25/share cash after the 2026-07-07 vote passed 11.31M for / 8,818 against. Shares were cashed out and delisted from Nasdaq. No tradable equity remains; the ticker is a closed file, not a setup.",
  "invalidation_trigger": "A daily close below $26.25 can no longer print — shares converted to $26.25 cash on the 2026-07-09 closing and were delisted from Nasdaq, so no US-listed equity exists to mark. Only a re-IPO or a new listed successor security would reopen this file.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-04-23: IKS Health (sub of Inventurus Knowledge Solutions, NSE: IKS) signed definitive merger to acquire TBRG at $26.25/share cash, ~$600M equity / ~$557M EV. Expected close Q3 2026.",
    "2026-04-23: IKS Health (US sub of NSE-listed Inventurus Knowledge Solutions) signed definitive merger to acquire TBRG at $26.25/share cash via merger sub IKS Next Horizon, Inc. ~$572M gross transaction value. Expected close Q3 2026.",
    "2026-06-22: HSR antitrust waiting period EXPIRED (8-K) — last U.S. regulatory gate cleared; deal now procedural, only the 7/7 shareholder vote + TopCo Indian-law special resolution remain.",
    "2026-04-23: IKS Health (US sub of NSE-listed Inventurus Knowledge Solutions) signed definitive merger to acquire TBRG at $26.25/share cash via merger sub IKS Next Horizon, Inc. (~$572M gross). Expected close Q3 2026.",
    "2026-07-09: IKS Health completed the acquisition; TruBridge is now a wholly owned subsidiary of Inventurus Knowledge Solutions (NSE: IKS). Common stock deregistered and delisted from Nasdaq Global Select.",
    "2026-07-10: Cantor Fitzgerald suspended its Neutral rating — routine coverage termination on a closed deal, not a fundamental call.",
    "Support agreements cover 4,094,178 shares (~27.3% of voting power; Pinetree, L6, Ocho), appraisal rights waived. TopCo support agreement covers ~62% of TopCo equity vs a 75%-of-votes-cast bar for the Indian-law debt-financing special resolution.",
    "Break fees: TruBridge $12.3M; IKS reverse termination fee $24.6M (2:1 favors close). Up to $670M debt commitment from Citigroup, Deutsche Bank, JPMorgan, Citibank. Outside date 2026-10-23.",
    "Pre-rumor standalone ~$16.24 (2026-04-02); 52wk $13.88-$26.51. Break-downside ~38% from ~$26. Cantor Neutral, PT $26.25 (= deal price, 2026-04-24).",
    "This is merger-arb carry (sub-1% gross), NOT narrative momentum. Do not count against the 2-5 high-conviction momentum slots. Earnings irrelevant under fixed cash price (Q1 2026 printed 2026-05-08). Reassess only on a confirmed deal-break.",
    "2026-07-07 special meeting: 11,305,399 for / 8,818 against / 19,927 abstain; 11,334,144 of 14,999,136 shares outstanding represented (~75.6% quorum). No holder exercised appraisal rights.",
    "Final deal economics: $26.25/share cash, ~$557M enterprise value, merger sub IKS Next Horizon, Inc. Outside date 2026-10-23 was never reached.",
    "Archive/DEAD status: no earnings, no filings, no price series forward. Any future TruBridge exposure would require Inventurus Knowledge Solutions (NSE-listed, India) — not accessible as a US-listed equity.",
    "Post-mortem for the special-situations sleeve: the entire re-rate from the ~$16.24 pre-rumor standalone (2026-04-02) to the $26.25 cap happened in a single halted gap on 2026-04-23. Everything after that date was ~$0.20 of carry against ~$10 of break risk — the reason a velocity book stood aside."
  ],
  "body_markdown": "## Current Thesis\nThe file is closed. IKS Health — the U.S. arm of NSE-listed Inventurus Knowledge Solutions — completed its acquisition of TruBridge on **2026-07-09** at **$26.25/share in cash**, roughly $557M enterprise value, with TruBridge surviving as a wholly owned subsidiary of IKS. The last open condition cleared on **2026-07-07**, when holders adopted the merger 11,305,399 for against 8,818 opposed, with 19,927 abstaining; 11,334,144 of 14,999,136 shares outstanding were represented, a ~75.6% quorum. **No stockholder exercised appraisal rights.** Common stock was deregistered and delisted from the Nasdaq Global Select Market. There is no US-listed equity here to trade, no forward price series to mark, and no residual narrative. Whatever the story was, it was fully monetized into a fixed number and paid out in cash.\n\n## Bull Case\n- **The deal paid in full.** Holders of record received $26.25 per share in cash at the 2026-07-09 closing — the exact consideration signed on 2026-04-23. No collar, no stock component, no earnout haircut.\n- **Zero completion friction at the end.** Appraisal rights went unexercised, meaning not one dissenting holder litigated valuation despite a 2026-05-10 commentary piece arguing the fixed-cash terms shortchanged owners and imposed a tax event. That is unusually clean for a sub-$600M take-private.\n- **The regulatory sequence never wobbled.** HSR waiting period expired 2026-06-22; the Indian-law TopCo special resolution supporting the debt financing cleared; the up-to-$670M commitment from Citigroup, Deutsche Bank, JPMorgan and Citibank funded on schedule. Outside date of 2026-10-23 was never approached.\n- **The vote was a formality by the time it happened.** Support agreements covering 4,094,178 shares (~27.3% of voting power — Pinetree Capital, L6 Holdings, Ocho Investments) were locked YES from signing; the final tally showed opposition of under 0.08% of votes cast.\n- **Underlying business rationale held together.** Rural and community-hospital EHR plus revenue-cycle management folded into a larger clinical-and-RCM outsourcing platform. That thesis now belongs to IKS shareholders in Mumbai.\n\n## Bear Case\n- **There is nothing left to own.** The ticker is deregistered. Any screen still surfacing TBRG is reading a stale symbol table.\n- **The only remaining exposure is offshore and inaccessible.** TruBridge economics now sit inside Inventurus Knowledge Solutions, listed on the NSE in India — outside the tradable universe of a US-brokerage book, and a completely different risk object (Indian mid-cap healthcare BPO, INR-denominated, different disclosure regime).\n- **The re-rate was never capturable by a momentum process.** The move from the ~$16.24 pre-rumor standalone (2026-04-02) to the cash cap happened inside a halted gap on 2026-04-23 — halted 9:21:59 a.m. ET, resumed 10:00 a.m. ET. There was no accumulating tape, no breakout retest, no leg to ride.\n- **Post-signing carry was structurally the wrong shape.** Roughly $0.20 of upside to the $26.25 cap against about $10 of downside to the pre-rumor standalone — on the order of 40:1 against, versus the >3:1 this playbook demands. A ~4–8% annualized gross return on a binary is not what concentrated conviction capital exists for.\n- **Coverage has been withdrawn.** Cantor Fitzgerald suspended its Neutral rating on 2026-07-10, the routine termination that follows a completed take-private. No sell-side eyes remain.\n\n## Setup & Price Structure\n- **Terminal print:** $26.25 cash per share, paid at the 2026-07-09 closing. The chart's last months were a horizontal line pinned a few cents under the cap — the standard behaviour of a fully de-risked arb once HSR clears.\n- **52-week range:** $13.88–$26.51. The $26.51 high sits marginally above the deal price, the brief overshoot on 2026-04-23 before spread discipline reasserted.\n- **Pre-rumor anchor:** ~$16.24 (2026-04-02), the last standalone mark before The Economic Times reported on 2026-04-13 that Jhunjhunwala-backed IKS was pursuing TruBridge at ~$600M. IKS confirmed non-binding talks on 2026-04-14; definitive agreement signed 2026-04-23.\n- **No moving averages, no support shelves, no volume profile.** Once a name trades on deal mechanics rather than fundamentals, technical structure stops carrying information — and now the series has stopped entirely.\n- **Beginner-trap read:** the failure mode this name invites is not peak retail sentiment or an over-extended MA. It is the archived-file trap — treating a pinned, capped, delisted symbol as a \"cheap, quiet, stable\" holding because the tape looks calm. Calm here means dead.\n\n## Catalyst Calendar (next 30 days)\n\n- **Indirect only:** Inventurus Knowledge Solutions reports on the Indian fiscal calendar and will discuss TruBridge integration there. That is NSE research, not a US-tradable event.\n\n## Elapsed catalysts\n\n- **2026-07-07 — ELAPSED.** Special meeting held virtually, 8:00 a.m. CT. Merger proposal adopted; advisory compensation proposal also approved (non-binding). *(passed 33d ago)*\n- **2026-07-09 — ELAPSED.** Merger closed. TruBridge became a wholly owned IKS Health subsidiary; Nasdaq delisting initiated. *(passed 31d ago)*\n- **2026-07-10 — ELAPSED.** Cantor Fitzgerald suspended coverage. *(passed 30d ago)*\n- **No forward catalysts.** No Q2 2026 print (the Q1 report on 2026-05-08 was the last, and reaffirmed the deal). No guidance, no investor day, no filings beyond the Form 25/Form 15 deregistration mechanics. *(passed 93d ago)*\n\n## What Would Change Our Mind\n- **A re-listing.** Sponsor-backed carve-outs occasionally return to public markets, but IKS is a strategic operator with a stated integration rationale, not a PE holder running a flip. A TruBridge re-IPO inside a five-year window is not a scenario worth reserving capital for.\n- **A newly listed successor security** — a US ADR on Inventurus, or a spin of the rural-hospital RCM asset. Neither has been signalled in any filing or release.\n- **A busted-closing reversal.** Not applicable: consideration has been paid and appraisal rights lapsed unexercised. There is no unwind path.\n- **Read-across value is where this file still earns its keep.** The completed comp — ~$557M EV for a rural-hospital EHR-plus-RCM asset, cash, no financing contingency at close — is a live valuation marker for other small-cap healthcare IT names that could draw strategic interest. That is the only reason to keep the page.\n\n## Correlation Notes\n- **No live correlation.** A cashed-out, delisted security has zero beta to anything. It correlates with nothing because it no longer prints.\n- **Historically**, from 2026-04-23 to 2026-07-09 TBRG behaved as a pure merger-arb instrument: near-zero correlation to the S&P 500, to healthcare IT peers, and to rates. Its only real drivers were antitrust headlines and vote-timing news. That decoupling is precisely why it was carry, not momentum.\n- **Sector read-across stays useful.** Small-cap healthcare IT and RCM names — the sub-$1B EHR and revenue-cycle cohort serving community and rural providers — now carry one more completed strategic comp. Cross-border acquirers with cheap capital have shown willingness to pay roughly 3x the disclosed break fee asymmetry to guarantee close (IKS reverse termination fee $24.6M vs TruBridge's $12.3M).\n- **Theme status: DEAD for this ticker.** The wider special-situations theme remains live as a hunting ground, but this specific instance is resolved and should be archived rather than monitored.",
  "first_seen": "2026-04-26",
  "last_analyzed": "2026-07-19T11:45:33+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}